Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab Soravtansine and Suvemcitug in Platinum-Resistant Ovarian Cancer
NCT07741630Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Aug 2026
- Primary completion
- Jun 2027
01
Overview
A Phase 2 trial of mirvetuximab soravtansine, suvemcitug in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Peking University Third Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
mirvetuximab soravtansinesuvemcitug
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07741630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07741630.